Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Safety data on AstraZeneca anaemia drug points to potential use in dialysis

Fri, 8th Nov 2019 19:47

FRANKFURT, Nov 8 (Reuters) - AstraZeneca said on
Friday that safety data on roxadustat underpinned the British
drugmaker's hopes for the anaemia drug to become a standard
treatment for patients with kidney disease.

It said pooled data from several late-stage trials showed
that roxadustat did not increase the risk of potentially deadly
cardiovascular complications like heart attacks and strokes when
used instead of epo, which is the standard treatment for
dialysis patients against lack of red blood cells from kidney
disease.
(Reporting by Ludwig Burger; Editing by Elaine Hardcastle)

Related Shares

More News

UPDATE 1-BT will maintain ties with skills group if it drops Prince Andrew as patron

(Adds details, background)LONDON, Nov 20 (Reuters) - Britain's BT has told a company promoting digital skills it would continue working with it if it dropped Prince Andrew as a patron.The British royal has been engulfed in a growing scandal since ...

20 Nov 19 10:52

BT will continue working with skills group if it drops Prince Andrew as patron

LONDON, Nov 20 (Reuters) - Britain's BT has told a company promoting digital skills to drop Prince Andrew as a patron if it wants to keep receiving support from the country's biggest broadband provider.Several major companies have sought to distan...

20 Nov 19 10:30

Friday broker round-up

(Sharecast News) - Whitbread: Barclays upgrades to overweight with a target price of 4,900p.

15 Nov 19 13:09

ShoreCap stays at 'buy' on AstraZeneca after EU approves Qtrilmet

(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation on shares of AstraZeneca following news that Brussels had approved its Qtrilmet treatment for controlling blood sugar levels in patients suffering from Type-2 diabetes.

15 Nov 19 11:25

Login to your account

Don't have an account? Click here to register.